Abstract
Barrett’s esophagus is common in Western countries, but progression to esophageal adenocarcinoma is uncommon. Chemoprevention therefore needs to consider whether benefits outweigh risks given an otherwise healthy population. This will depend on the particular population at risk and the relative safety of a potential preventive agent. Most evidence regarding the potential benefit of chemoprevention of Barrett’s esophagus and prevention of progression to esophageal adenocarcinoma is based on observational studies such as case–control and cohort studies. Given the potential benefits and relatively low risks, patients with BE should receive once-daily PPI therapy, but routine use of twice-daily PPI is not recommended unless necessitated by poor control of reflux symptoms or esophagitis. Recent data suggest that the inverse associations between aspirin/NSAID use and esophageal adenocarcinoma may be the result of reducing neoplastic progression (from metaplasia to dysplasia and carcinoma) rather than initiation of Barrett’s esophagus. While substantial associative data suggest a potential benefit of aspirin and nonaspirin NSAIDs in reducing the risk of progression of Barrett’s esophagus, the low risk of progression and the potential risks (gastrointestinal bleeding, complicated ulcer disease, hemorrhagic stroke) do not warrant routine use, unless dictated by cardiovascular risk. Chemoprevention after mucosal ablation in those at highest risk of post-ablation recurrence (dysplastic Barrett’s) is currently under investigation.
Similar content being viewed by others
Abbreviations
- BE:
-
Barrett’s esophagus
- EA:
-
Esophageal adenocarcinoma
- GERD:
-
Gastroesophageal reflux disease,
- HGD:
-
High-grade dysplasia
- OR:
-
Odds ratio
- 95% CI:
-
95% Confidence intervals
- PPI:
-
Proton pump inhibitor
- ROS:
-
Reactive oxygen species
- COX:
-
Cyclooxygenase
- NSAID:
-
Nonsteroidal anti-inflammatory drug
- CEIM:
-
Complete eradication of intestinal metaplasia
References
Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149:302–317.
Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.
Desai TK, Krishnan K, Samala N, Singh J, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s esophagus: a meta-analysis. Gut. 2012;61:970–976.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.
Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.
Dunbar K, Souza RF, Spechler SJ. The effect of proton pump inhibitors on Barrett’s esophagus. Gastroenterol Clin N Am. 2015;44:415–424.
Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett’s esophagus. J Gastroenterol. 2017;52:767–776.
Liao LM, Vaughn TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–445.
Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygense inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus:a meta-analysis. Br J Cancer. 2014;110:2378–2388.
Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocercinoma. PLoS Med. 2007;2:442–454.
Huo X, Zhabng X, Yu C, et al. Aspirin prevents NF-ΚB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett’s esophagus. Gut. 2018;67:606–615.
Falk G, Buttar NS, Foster NR, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E2 in patients with Barrett’s esophagus. Gastroenterology. 2012;143:917–926.
Schneider JL, Zhao WK, Corley DA. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett’s esophagus. Dig Dis Sci. 2015;60:436–443. https://doi.org/10.1007/s10620-014-3349-2.
Omer ZB, Ananthakrisnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol. 2012;10:722–727.
Thrift AP, Anderson LA, Murray LJ, et al. Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett’s esophagus. Am J Gastroenterol. 2016;111:1528–1535.
Spechler SJ, Sharma P, Souza R, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline:diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.
Stairs DB, Kong J, Lynch JP. Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia. Prog Mol Biol. 2010;96:231–270.
Fitzgerald RE, Abdalla S, Onuegbusi BA, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51:316–322.
Song S, Guha S, Liu K, Buttar NS, Bresdalier RS. Cox-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett’s oesophagus and oesophageal carcinoma. Gut. 2007;c56:1512–1521.
Singh S, Garg SK, Singh PP, et al. Acid-supressive medications and risk of oesophageal carcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–1237.
Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in pateitns with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:382–388.
Cuzick J, Otto F. Brown PH, et.a l. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention:an international consensus statement. Lancet Oncol. 2009;10:501–507.
Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, stains, proton pump inhibitors and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.
Anderson LA, Johnston BT, Watson RGP, et al. Nonsteroidal anti-inflammatory drugs and the esophageal-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–4982.
Vaugn TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s esophagus:a prospective study. Lancet Oncol. 2005;6:945–952.
Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. JNCI. 2007;99:545–557.
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow up of randomized trials. The Lancet. 2010;376:1741–17501.
Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16:173–186.
Bibbins-Domingo K, on behalf of the U.S. Preventive Services Task Force. Asprin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendations Statement. Ann Int Med. 2016;164:836–845.
Das D, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.
Spence AD, Busby J, Johnston BT, et al. Low-dose aspirin does not increase survival in 2 independent population-based cohorts of patients with esophageal or gastric cancer. Gastroenterology. 2018;154:849–860.
Peng S, Huo X, Rezaei D, et al. In Barrett’s esophagus patients and cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:G129–G139.
Song S, Guha S, Liu K, Buttar NS, Bresalier RS. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett’s oesophagus and oesophageal adenocarcinoma. Gut. 2007;11:1512–1521.
Joe AK, Scnoll-Sussman F, Bresalier RS, et al. Phase Ib randomized, double-blnded, placebo-controlled, dose escalation study of polyphenon E in patients with Barrett’s esophagus. Cancer Prev Res. 2015;8:1131–1137.
Shaheen N, Overholt B, Sampliner R, et al. Durability of radiofrequency ablation in Barett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.
Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in pateints successfully treated for Barrettt’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187–195.
Pasricha S, Buksiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1840–1847.
Cotton CC, Wolf A, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus :endoscopic findings and anatomic location. Gastrointest Endosc. 2015;81:1362–1369.
Guthikonda A, Cotton CC, Madanick RD, et al. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2017;112:87–94.
Cotton CC, Wolf WA, Overholt BF, et al. Late recurrence of Barrett’s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017;153:681–688.
Funding
National Cancer Institute Division of Cancer Prevention Grant TO-RFP S-2014 (NCT02521285).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author reports no conflicts of interest.
Rights and permissions
About this article
Cite this article
Bresalier, R.S. Chemoprevention of Barrett’s Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 63, 2155–2162 (2018). https://doi.org/10.1007/s10620-018-5149-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5149-6